Uric acid lowering to prevent kidney function loss in diabetes

The preventing early renal function loss (PERL) allopurinol study

David M. Maahs, Luiza Caramori, David Z I Cherney, Andrzej T. Galecki, Chuanyun Gao, Diana Jalal, Bruce A. Perkins, Rodica Pop-Busui, Peter Rossing, Michael Mauer, Alessandro Doria

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.

Original languageEnglish (US)
Pages (from-to)550-559
Number of pages10
JournalCurrent diabetes reports
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2013

Fingerprint

Allopurinol
Uric Acid
Type 1 Diabetes Mellitus
Kidney
Kidney Diseases
Diabetic Nephropathies
Disease Progression
Blood Pressure
Morbidity
Costs and Cost Analysis
Glucose
Mortality
Serum
Population
Therapeutics

Keywords

  • Allopurinol
  • Diabetes
  • Diabetic kidney disease
  • Diabetic nephropathy
  • Glomerular filtration rate
  • Kidney disease
  • PERL trial
  • Randomized clinical trial
  • Type 1 diabetes
  • Uric acid

Cite this

Uric acid lowering to prevent kidney function loss in diabetes : The preventing early renal function loss (PERL) allopurinol study. / Maahs, David M.; Caramori, Luiza; Cherney, David Z I; Galecki, Andrzej T.; Gao, Chuanyun; Jalal, Diana; Perkins, Bruce A.; Pop-Busui, Rodica; Rossing, Peter; Mauer, Michael; Doria, Alessandro.

In: Current diabetes reports, Vol. 13, No. 4, 01.08.2013, p. 550-559.

Research output: Contribution to journalArticle

Maahs, DM, Caramori, L, Cherney, DZI, Galecki, AT, Gao, C, Jalal, D, Perkins, BA, Pop-Busui, R, Rossing, P, Mauer, M & Doria, A 2013, 'Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study', Current diabetes reports, vol. 13, no. 4, pp. 550-559. https://doi.org/10.1007/s11892-013-0381-0
Maahs, David M. ; Caramori, Luiza ; Cherney, David Z I ; Galecki, Andrzej T. ; Gao, Chuanyun ; Jalal, Diana ; Perkins, Bruce A. ; Pop-Busui, Rodica ; Rossing, Peter ; Mauer, Michael ; Doria, Alessandro. / Uric acid lowering to prevent kidney function loss in diabetes : The preventing early renal function loss (PERL) allopurinol study. In: Current diabetes reports. 2013 ; Vol. 13, No. 4. pp. 550-559.
@article{67fe758cfd154fd8b22a2af72313b8db,
title = "Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study",
abstract = "Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.",
keywords = "Allopurinol, Diabetes, Diabetic kidney disease, Diabetic nephropathy, Glomerular filtration rate, Kidney disease, PERL trial, Randomized clinical trial, Type 1 diabetes, Uric acid",
author = "Maahs, {David M.} and Luiza Caramori and Cherney, {David Z I} and Galecki, {Andrzej T.} and Chuanyun Gao and Diana Jalal and Perkins, {Bruce A.} and Rodica Pop-Busui and Peter Rossing and Michael Mauer and Alessandro Doria",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/s11892-013-0381-0",
language = "English (US)",
volume = "13",
pages = "550--559",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Uric acid lowering to prevent kidney function loss in diabetes

T2 - The preventing early renal function loss (PERL) allopurinol study

AU - Maahs, David M.

AU - Caramori, Luiza

AU - Cherney, David Z I

AU - Galecki, Andrzej T.

AU - Gao, Chuanyun

AU - Jalal, Diana

AU - Perkins, Bruce A.

AU - Pop-Busui, Rodica

AU - Rossing, Peter

AU - Mauer, Michael

AU - Doria, Alessandro

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.

AB - Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.

KW - Allopurinol

KW - Diabetes

KW - Diabetic kidney disease

KW - Diabetic nephropathy

KW - Glomerular filtration rate

KW - Kidney disease

KW - PERL trial

KW - Randomized clinical trial

KW - Type 1 diabetes

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=84880135111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880135111&partnerID=8YFLogxK

U2 - 10.1007/s11892-013-0381-0

DO - 10.1007/s11892-013-0381-0

M3 - Article

VL - 13

SP - 550

EP - 559

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 4

ER -